Menopause transition and cardiovascular disease risk
- PMID: 38555760
- DOI: 10.1016/j.maturitas.2024.107974
Menopause transition and cardiovascular disease risk
Abstract
The risk of cardiovascular disease (CVD) notably increases in the fifth decade of a woman's life, coinciding with the onset of menopause and occurring 10 years later than the similar age-related increase in men. Menopause marks a significant transition in a woman's life and is accompanied by cardiometabolic changes, including a shift in body composition, increased blood pressure, disruptions in lipoproteins, and insulin resistance. There is increasing evidence that the menopause transition is a risk factor for CVD, independent of age-related changes, especially considering that the earlier the onset of menopause, the greater is the CVD risk. Further, menopause-related symptoms such as vasomotor symptoms, sleep disturbances, and mood changes may all have a direct impact on CVD risk. In this review, we summarize the current literature regarding CVD in midlife women, focusing on the cardiometabolic changes related to ovarian aging versus chronological aging, as well as those related to specific menopause characteristics, including age, type of menopause and the use of menopause hormone therapy.
Keywords: Cardiovascular disease; Estrogen; Heart disease; Hormone therapy; Menopause; Midlife.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no competing interest.
Similar articles
-
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.Circulation. 2020 Dec 22;142(25):e506-e532. doi: 10.1161/CIR.0000000000000912. Epub 2020 Nov 30. Circulation. 2020. PMID: 33251828 Review.
-
Cardiovascular Disease in Women: Does Menopause Matter?Curr Opin Endocr Metab Res. 2022 Dec;27:100419. doi: 10.1016/j.coemr.2022.100419. Epub 2022 Oct 6. Curr Opin Endocr Metab Res. 2022. PMID: 37274015 Free PMC article.
-
Understanding of and clinical approach to cardiometabolic transition at the menopause.Climacteric. 2024 Feb;27(1):68-74. doi: 10.1080/13697137.2023.2202809. Epub 2023 May 24. Climacteric. 2024. PMID: 37224871 Review.
-
Reproductive aging, menopause, and health outcomes.Ann N Y Acad Sci. 2010 Aug;1204:169-78. doi: 10.1111/j.1749-6632.2010.05526.x. Ann N Y Acad Sci. 2010. PMID: 20738288
-
Cardiovascular and physiological risk factors in women at mid-life and beyond.Can J Physiol Pharmacol. 2024 Aug 1;102(8):442-451. doi: 10.1139/cjpp-2023-0468. Epub 2024 May 13. Can J Physiol Pharmacol. 2024. PMID: 38739947 Review.
Cited by
-
Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives.Nutrients. 2024 Dec 13;16(24):4313. doi: 10.3390/nu16244313. Nutrients. 2024. PMID: 39770936 Free PMC article. Review.
-
Metabolic Syndrome and Survival Outcomes in Endometrial Cancer.Cureus. 2024 May 15;16(5):e60324. doi: 10.7759/cureus.60324. eCollection 2024 May. Cureus. 2024. PMID: 38883006 Free PMC article. Review.
-
Examining the relationship between symptoms and quality of life related to menopausal period of women with gynecologic cancer: a cross-sectional study.Support Care Cancer. 2025 Jul 11;33(8):683. doi: 10.1007/s00520-025-09735-9. Support Care Cancer. 2025. PMID: 40643737
-
The intersection between menopause and depression: overview of research using animal models.Front Psychiatry. 2024 Jul 15;15:1408878. doi: 10.3389/fpsyt.2024.1408878. eCollection 2024. Front Psychiatry. 2024. PMID: 39081530 Free PMC article. Review.
-
The Influence of Concurrent Autoimmune Thyroiditis on the Cardiometabolic Consequences of Cabergoline in Postmenopausal Women.Metabolites. 2025 Jan 1;15(1):9. doi: 10.3390/metabo15010009. Metabolites. 2025. PMID: 39852352 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical